Medicamen Biotech Reports 30.75% PAT Growth Amid Rising Debt and Liquidity Concerns

Aug 12 2025 07:53 PM IST
share
Share Via
Medicamen Biotech announced its financial results for the quarter ending June 2025, revealing a Profit After Tax of Rs 4.55 crore, a year-on-year increase. However, the company faces challenges with rising interest expenses, declining cash reserves, and an elevated debt-equity ratio, indicating a complex financial landscape.
Medicamen Biotech has recently reported its financial results for the quarter ending June 2025, with the announcement made on August 12, 2025. The company operates within the Pharmaceuticals & Biotechnology industry and is classified as a microcap entity.

In the latest financial period, Medicamen Biotech's Profit After Tax (PAT) for the last six months reached Rs 4.55 crore, reflecting a year-on-year growth of 30.75%. This positive trend in PAT indicates a favorable near-term outlook for the company's profitability.

However, the financial results also highlight some challenges. The interest expense for the quarter surged to Rs 1.15 crore, marking a significant increase compared to previous quarters, which suggests a rise in borrowings. Additionally, the cash and cash equivalents have reached their lowest point in the last six half-yearly periods at Rs 3.76 crore, indicating potential short-term liquidity concerns. Furthermore, the debt-equity ratio has risen to 0.16 times, the highest in the last five half-yearly periods, suggesting that the company is increasingly relying on debt to finance its operations.

Overall, Medicamen Biotech has experienced evaluation changes in its financial metrics, reflecting a complex landscape of growth and challenges.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
Why is Arkade falling/rising?
1 hour ago
share
Share Via
Why is Premium Plast falling/rising?
1 hour ago
share
Share Via
Why is Sanofi Consumer falling/rising?
1 hour ago
share
Share Via
Why is Ola Electric falling/rising?
1 hour ago
share
Share Via